XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.3
STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 12, 2023
Jun. 20, 2024
Feb. 29, 2024
Oct. 31, 2023
Oct. 20, 2023
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Jan. 31, 2024
Stock-based compensation to stock options           $ 177,734 $ 205,317          
Unvested performance-based stock options granted           418,945 88,911          
Number of shares outstanding granted               264,945 238,838 60,566 95,167  
Stock-based compensation related to restricted stock units           $ 171,289 $ 185,019          
Number of outstanding shares of restricted stock units           279,700            
Unvested performance-based stock options granted estricted stock units           274,549 59,842          
Restricted stock units number of shares outstanding granted               184,443 152,432 40,707 22,343  
Withholding taxes related to restricted stock units, shares           54,691            
Fees and expenses       $ 9,109,117 $ 4,573,948 $ 9,224,056            
Gross proceeds           10,000,006            
Exercise price per share         $ 2.12             $ 5.46
Exercise price         $ 0.0001              
Description of securities purchase agreement The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company’s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission   an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the “January 2024 Private Warrants”) to purchase up to 1,831,503 shares of the Company’s common stock (the “January 2024 Private Warrant Shares”) in a concurrent private placement (the “Private Offering” and together with the January 2024 RD Offering, the “January 2024 Offering”). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46   ) 1,325,000 shares of common stock (the “October 2023 Shares”), of the Company and (ii) pre-funded warrants (the “October 2023 Pre-Funded Warrants”) to purchase up to 1,033,491 shares of the Company’s common stock (the “October 2023 Pre-Funded Warrant Shares”). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the “October 2023 Private Warrants”) to purchase up to 2,358,491 shares of the Company’s common stock (the “October 2023 Private Warrant Shares”) in a concurrent private placement (the “October 2023 Private Offering” and together with the October 2023 RD Offering, the “October 2023 Offering”). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023              
Distributable value of dividend           $ 100            
Stock Warrants [Member]                        
Exercise price   $ 1.88                    
Purchase of warrant of common stock series A   4,849,915                    
Description of existing holder purchase of warrants   (i) lower the exercise price to $1.88 per share for the 3,233,277 Existing Warrants being exercised pursuant to the Inducement Letter and (ii) issue to the Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the “June 2024 Series A Warrants”) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the “June 2024 Series B Warrants” and together with the June 2024 Series A Warrants, the “June 2024 Inducement Warrants”). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the Existing Warrants by the Exercising Holder (the “Warrant Inducement”)                    
Exercising holder released shares           1,443,277            
Warrants to purchase   3,233,277                    
Gross proceeds from exercise of Existing Warrants   $ 6,078,561                    
2024 Placement Agent Warrants                        
Shares of Common Stock           91,575            
Exercise price           $ 6.825            
Convertible Series A Preferred Stocks [Member]                        
Convertible preferred stock were outstanding           4,030            
Aggregate value           $ 403,000            
Conversion price           $ 75.45            
Convertible shares           $ 1.33            
Distributable value of dividend           $ 100            
Distributable value of dividend additional           100            
2023 Equity Distribution Agreement [Member]                        
Purchase of warrant shares           $ 1,033,491